20 mg, enteric-coated tablets
Escinum
Reparil and Reparil Dragées are different trade names for the same drug.
important information for the patient.
This medicine should always be taken exactly as described in the patient leaflet or as directed by a doctor or pharmacist.
Reparil is a medicine used for swelling after local injuries.
Before starting to take Reparil, the patient should discuss it with their doctor or pharmacist.
During treatment with Reparil, kidney function should be monitored.
Administration of Reparil to children under 7 years of age is contraindicated.
The patient should tell their doctor or pharmacist about all medicines they are taking or have recently taken, as well as any medicines they plan to take.
Reparil may enhance the effect of anticoagulant medicines.
Concomitant use of Reparil with aminoglycoside antibiotics should be avoided due to the potential increased toxic effect of these antibiotics on the kidneys.
Antibiotics such as cefalotin and ampicillin may increase the concentration of escin in serum, so it is not recommended to administer these medicines with Reparil.
Reparil should be taken after a meal. The tablet should be swallowed whole, with a glass of water.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medicine.
Due to the lack of studies in pregnant women and insufficient animal data, Reparil should not be used in pregnant women.
Due to the lack of data on the passage of escin into breast milk, Reparil should not be used in breastfeeding women.
Reparil has no influence or negligible influence on the ability to drive and use machines.
If the patient has previously been diagnosed with intolerance to some sugars, they should consult their doctor before taking the medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is considered "sodium-free".
This medicine should always be taken exactly as described in the patient leaflet or as directed by a doctor or pharmacist. In case of doubt, the patient should consult their doctor or pharmacist.
Unless the doctor has prescribed otherwise, Reparil should be taken as follows:
Reparil should be taken after a meal. The tablet should be swallowed whole, with a glass of water.
In case of overdose, the patient should immediately consult their doctor or pharmacist.
The patient should take the next tablet as scheduled.
A double dose should not be taken to make up for a missed dose.
Like all medicines, Reparil can cause side effects, although not everybody gets them.
Side effects may occur:
The following side effects have been reported:
very rarely: hypersensitivity reactions such as urticaria;
uncommonly: gastrointestinal disorders.
In case of a hypersensitivity reaction, Reparil should be discontinued.
If the patient experiences any side effects, including any side effects not listed in the leaflet, they should inform their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
tel.: + 48 (22) 49 21 301
fax: + 48 (22) 49 21 309
website: https://smz.ezdrowie.gov.pl
Reporting side effects will help to gather more information on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
Store in a temperature below 25°C. Store in the original packaging to protect from moisture.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Blisters (PVC/Al) containing 10 enteric-coated tablets: 20, 40, or 100 enteric-coated tablets in a cardboard box.
For more detailed information, the patient should contact the marketing authorization holder or the parallel importer.
Viatris Healthcare Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Madaus GmbH
51101 Cologne
Germany
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Authorization number in the Czech Republic, the country of export: 85/186/71-C
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.